We recently published a list of Why These 10 Firms Recorded Double-Digit Gains Last Week. In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other firms that recorded double-digit gains last week.
Ten companies finished the past trading week on a high note, outperforming the three major indices with double-digit gains amid a flurry of catalysts, including upcoming earnings releases, that sparked buying appetite.
Week-on-week, the Nasdaq rallied by 6.7 percent, the S&P 500 clocked in a 4.59-percent gain, while the Dow Jones was up by 2.48 percent.
In this article, we have listed last week’s top 10 performing stocks and detailed the reasons behind their gains. The stocks were chosen based on the highest percentage increase in closing prices on April 25 as against their prices on April 17, or the week prior.
To come up with the list, we considered only the companies with a $2-billion market capitalization and a $5-million trading volume.
Copyright: nexusplexus / 123RF Stock Photo
Tempus AI Inc. (NASDAQ:TEM)
Telehealth company Tempus AI saw its share prices surge by 30.78 percent week-on-week to finish at $52.90 on Friday versus the $40.45 registered on April 17 as investors repositioned portfolios ahead of its upcoming earnings release while cheering its newly inked partnership with AstraZeneca and Pathos AI.
According to the company, it is scheduled to release the results of its first quarter operational and financial highlights on Tuesday, May 6, 2025.
In other news, Tempus AI Inc. (NASDAQ:TEM) clinched a new $200-million deal with AstraZeneca and Pathos AI for the development of a multimodal foundation model in oncology. The total amount includes data licensing and model development fees.
The model, which will utilize TEM’s de-identified oncology data, will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.
Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care.
“Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale,” said TEM CEO Eric Lefkofsky.
“Tempus has spent the last decade investing billions of dollars into collecting the necessary data needed for a foundation model of this kind to take shape. We look forward to working with AstraZeneca and Pathos to apply AI-enabled solutions to advance therapies in an effort to help patients live longer and healthier lives,” he added.
